EU/3/16/1693 - orphan designation for treatment of retinitis pigmentosa

Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene

Overview

On 14 July 2016, orphan designation (EU/3/16/1693) was granted by the European Commission to GenSight Biologics, France, for adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene for the treatment of retinitis pigmentosa.

What is retinitis pigmentosa?

Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of sight. In patients with retinitis pigmentosa, cells in the retina (the light-sensitive surface at the back of the eye) become damaged and eventually die.

Retinitis pigmentosa is a long-term debilitating disease because it causes the patient's sight to get worse, eventually leading to blindness.

What is the estimated number of patients affected by the condition?

At the time of designation, retinitis pigmentosa affected less than 3.7 in 10,000 people in the European Union (EU). This was equivalent to a total of fewer than 190,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

* Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 513,700,000 (Eurostat 2016).

What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for treating retinitis pigmentosa. Patients with the condition were given sunglasses to slow down the damage to the retina, genetic counselling (discussion of the risks of passing the condition on to children) and general support.

How is this medicine expected to work?

In patients with retinitis pigmentosa, the light-sensitive cells in the retina gradually die. The medicine consists of a virus that has been modified to contain copies of a gene that produces a light-sensitive pigment. When injected into the eye, the medicine is expected to carry this gene into nerve cells in the retina that are not normally sensitive to light. This would enable these cells to produce the pigment and become responsive to light, so helping to restore the action of the retina and reduce symptoms of the condition.

The virus used in this medicine (adeno-associated virus) does not cause disease in humans.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with this medicine in patients with retinitis pigmentosa had been started.

At the time of submission, the medicine was not authorised anywhere in the EU for retinitis pigmentosa or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 16 June 2016 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/16/1693 : Public summary of opinion on orphan designation: Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene for the treatment of retinitis pigmentosa

Reference Number: EMA/COMP/446355/2016

Key facts

• Active substance:
  Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene
• Intended use:
  Treatment of retinitis pigmentosa
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/16/1693
• Date of designation:
  14/07/2016
• Sponsor:

  GenSight Biologics; 74 rue du Faubourg Saint-Antoine; 75012 Paris; France; Tel. [phone]; Fax [phone]; E-mail: [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.